Ductal Carcinoma In Situ

  • Anjali R. Thawani
  • Lillian M. ErdahlEmail author


The diagnosis and management of ductal carcinoma in situ is constantly evolving. Ductal carcinoma in situ is considered a “preinvasive” cancer of the breast, often considered a nonobligate precursor to invasive disease. It is generally discovered on screening mammography by the presence of calcifications. Key components of the history and physical exam can aid the surgeon in determining important aspects in the care of the patient. Treatment includes surgery, in the form of lumpectomy or mastectomy, radiation therapy (RT), and hormone therapy (HT). Axillary staging is usually not necessary unless invasive disease is found. Genomic testing can aid the clinician in making decisions regarding the need for adjuvant therapy, thereby individualizing care for each patient and avoiding unnecessary morbidity.


Ductal carcinoma in situ Evaluation Treatment Recurrence Prognosis Practical Algorhythm Genomics Surgery 


  1. 1.
    Silverstein M, Lagios M. Ductal carcinoma in situ. In: Keurer H, editor. Keurer’s breast surgical oncology. New York: The McGraw Hill Companies; 2010. p. 189–207.Google Scholar
  2. 2.
    Lagios M. Duct carcinoma in situ: a Gordian knot untied. In: Scott-Conner C, Dirbas F, editors. Breast surgical techniques and interdisciplinary management. New York: Springer; 2011. p. 623–31.Google Scholar
  3. 3.
    Sanders M, Schuyler P, Dupont W, Page D. The natural history of low grade ductal carcinoma in suit of the breast in women treated by biopsy only revealed over 30 years of long term follow-up. Cancer. 2005;103:2481–4.CrossRefGoogle Scholar
  4. 4.
    Rosen P, Senie R, Schottenfeld D, Ashikari R. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg. 1979;1989:377–82.CrossRefGoogle Scholar
  5. 5.
    Holland R, Hendriks J, Verbeek A, et al. Extend, distribution, and mammographic/histological correclations of breast ductal carcinoma in situ. Lancet. 1990;335:519–22.CrossRefGoogle Scholar
  6. 6.
    Eva SS. Rating the risk factors for breast cancer. Ann Surg. 2003;237(4):474–82.Google Scholar
  7. 7.
    National Comprehensive Cancer Network. Breast cancer. Genetic/familial high-risk assessment: breast and ovarian. Version 3.2017. Accessed 2/2018.
  8. 8.
    Holland R, Peterse J, Millis R, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994;11:167–80.PubMedGoogle Scholar
  9. 9.
    Silverstein MJ, Poller D, Waisman J, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345:1154–7.CrossRefGoogle Scholar
  10. 10.
    Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–18.CrossRefGoogle Scholar
  11. 11.
    UK Coordinating Committee on Cancer Research (UKCCR), Ductal Carcinoma in Situ (DCIS) Working Party. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situe of the breast in the UK, Australia, and New Zealand: randomized controlled trial. Lancet. 2003;362:95–102.CrossRefGoogle Scholar
  12. 12.
    Viani GA, Stefano EJ, Alfonso SL, et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a metaanalysis of randomized trials. Radiat Oncol. 2007;2:28–39.CrossRefGoogle Scholar
  13. 13.
    Fisher B, Constantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328:1581–6.CrossRefGoogle Scholar
  14. 14.
    Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.CrossRefGoogle Scholar
  15. 15.
    Julien J, Bijker N, Fentiman I, et al. Radiotherapy in breast conserving treatment for ducal carcinoma in situ: first results of EORTC randomized phase III trial 10853. Lancet. 2000;355:528–33.CrossRefGoogle Scholar
  16. 16.
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.CrossRefGoogle Scholar
  17. 17.
    Solin LJ, Gray R, Bahner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.CrossRefGoogle Scholar
  18. 18.
    Rackovich E, Nofech-Mozes S, Henna W, et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152(2):389–98.CrossRefGoogle Scholar
  19. 19.
    Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014;21(3):704–16.CrossRefGoogle Scholar
  20. 20.
    Rosenberger LH, Mamtani A, Fuzesi S, et al. Early adoption of the SSO-ASTRO consensus guidelines on margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: initial experience from Memorial Sloan Kettering Cancer Center. Ann Surg Oncol. 2016;23(10):3239–46.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Surgical OncologyAMITA Health SystemElk Grove VillageUSA
  2. 2.Department of SurgeryUniversity of IowaIowa CityUSA

Personalised recommendations